Vesalius Biocapital Partners

What Vesalius Biocapital Partners does

Vesalius Biocapital Partners Sàrl is a Luxembourg-domiciled venture capital firm founded in 2007 that manages two funds with more than €150 million of committed capital, deploying equity into European life science companies. The firm invests across all stages of development, with a stated focus on therapeutics, medical devices, and diagnostics, and invests up to €10 million per portfolio company across multiple financing rounds. It acts as lead investor in the majority of its rounds and typically secures board representation in portfolio holdings.

The firm's underlying "product" is its venture capital funds rather than a technology platform. Its investment engine relies on a relationship-driven sourcing model anchored by partnership agreements with research institutions including VIB (Flanders Life Sciences Research Institute) and Fraunhofer, as well as a senior team of life science operating veterans who provide strategic guidance, hiring support, and exit planning to portfolio companies. The active and historical portfolio spans approximately 20 companies, including Exact Imaging's micro-ultrasound platform, Trod Medical's prostate ablation device, Promethera's liver cell therapies, Complix's Alphabody platform, Omeicos Therapeutics' atrial fibrillation programs, Genomic Vision's molecular combing technology, and Ncardia's cardiomyocyte assay systems.

The business model generates revenue through standard venture capital economics: recurring management fees on committed capital plus carried interest on successful realizations. The firm serves institutional and private Limited Partners that allocate to European life science venture, and its end-clients are the European life science entrepreneurs and corporate spin-outs receiving capital and operating support. With only 1-10 employees disclosed and no public revenue or third-fund announcement, the firm operates as a small, specialized, partnership-driven asset manager rather than a scaled institutional platform.

Name

Vesalius Biocapital Partners

Legal name

Vesalius Biocapital Partners Sàrl

Website

https://vesaliusbiocapital.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

Vesalius Biocapital Partners is a Luxembourg-based venture capital firm founded in 2007 that manages two funds with over €150 million committed to early and growth-stage European life science companies in therapeutics, medical devices, and diagnostics, acting as lead investor in most rounds.

Ownership category

akta.pro rank

Product category

Venture Capital (Life Sciences)

NAICS

Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

akta.pro secondary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

• Life science venture capital
• Biotech equity financing
• Medical device investment
• Therapeutics venture funding
• European early-stage investing

Headquarters

HQ city

Strassen

HQ country

Luxembourg

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others

Revenue model

1. Venture Capital Fund Management: Vesalius Biocapital generates returns through management fees and carried interest from venture capital funds raised since 2007. They manage two funds with over €150 million under management, investing up to €10 million in a single portfolio company over multiple financing rounds.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Vesalius Biocapital Partners provides equity venture capital financing to young European life science companies active in therapeutics, medical devices, and diagnostics. Through two funds totaling more than €150 million under management (raised since 2007), the firm invests across all stages of development, committing up to €10 million per portfolio company over multiple financing rounds and typically acting as lead investor with a board seat. The firm has contributed to developing 20 companies since inception.

Product overview

Vesalius Biocapital Partners is a Luxembourg-based venture capital firm offering investment funds rather than a traditional product company. The firm manages over €150 million across two venture capital funds focused on European life science companies in therapeutics, medical devices, and diagnostics. Their portfolio includes 20 companies across various stages, with investments ranging from seed funding to €10 million commitments per company. As an active investor, they lead or co-lead investments and hold board seats. The portfolio encompasses diverse technologies including controlled breathing devices, micro-ultrasound imaging, cell therapies, enzymatic systems, protein therapeutics platforms, and genomic analysis tools.

Differentiator

Problem solved

Functional benefit

Products and services

• Vesalius Biocapital Venture Capital Funds Venture capital investment funds providing equity financing to European life science companies in therapeutics, medical devices, and diagnostics. The firm manages over €150 million across two funds and has contributed to developing 20 companies since inception, investing up to €10 million per company across multiple financing rounds, typically as lead investor and always holding a board seat.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• VIB (Flanders Life Sciences Research Institute)coreStrategic or Co-development PartnerVIB is a Centre of Excellence performing basic research with strong focus on translating scientific results into novel pharmaceutical applications. Vesalius Biocapital has a non-exclusive partnership agreement with VIB to foster spin-off processes and potentially act as lead or co-lead investor.
• Fraunhofer (Europe's largest application-oriented research organization)coreStrategic or Co-development PartnerFraunhofer is Europe's largest application-oriented research organization. Vesalius Biocapital has partnerships with Fraunhofer institutes as part of their network of Centres of Excellence for deal flow and technology transfer.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Sofinnova Partners: Paris-based European venture capital firm with a dedicated life sciences strategy investing in therapeutics and medtech from seed to late stage. Direct comparable as a sector-specialist European life sciences VC of similar vintage.
• Forbion: Netherlands-based venture capital firm focused on life sciences, building companies from early-stage through late-stage clinical development. Highly comparable in vertical specialization and European focus.
• LSP (Life Sciences Partners): Amsterdam-headquartered VC firm exclusively investing in life sciences, including therapeutics, medical devices, and diagnostics. Closely matched business model, sector focus, and European footprint.
• Kurma Partners: Paris-based venture capital firm with a dedicated life sciences strategy financing early- to growth-stage European biotech and medtech companies. Comparable in scale, sector specialization, and lead-investor approach.
• Fountain Healthcare Partners: Dublin-based life sciences venture capital firm investing in early- and growth-stage therapeutics, medical devices, and diagnostics in Europe. Comparable sector focus and stage orientation.
• Epidarex Capital: Edinburgh-based early-stage life sciences venture capital firm building companies across European and US biotech hubs. Comparable focus on early-stage therapeutics with a similar venture-building approach.
• Inventages Venture Capital: Swiss-based venture capital firm with a focus on life sciences and nutrition, investing across Europe and globally. Comparable in sector specialization and life science stage focus.
• Seroba Life Sciences: European life sciences venture capital firm investing in early- to mid-stage medical devices, diagnostics, and therapeutics. Comparable in sector focus, European geography, and company-building orientation.

Broad incumbents

• Novo Holdings (Novo Seeds): Danish investment holding company managing the Novo Nordisk Foundation's venture activities including early-stage life sciences investing through Novo Seeds. Overlaps in life science VC but operates at significantly larger scale and broader scope.
• Edmond de Rothschild Private Equity Life Sciences: European asset manager with dedicated life sciences private equity strategies, including venture and growth-stage. Overlaps in life science investing but operates as part of a larger multi-strategy platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments57 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vesalius Biocapital Partners